Sarcoma, Ewing's Clinical Trial
Official title:
Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment
The purpose of the study is to assess the functional outcome, quality of life and late sequelae in a representative sample of 600 long-term survivors of Ewing sarcoma and to build a unique clinical and functional data pool of the underlying cohort of 3000 Ewing sarcoma patients with a follow-up of 3 decades.
Trial objective: As survival rates of bone sarcoma patients have been raised owing to
improved treatment strategies the focus of investigations is now on the medical, social, and
economic sequelae of intensive multimodal treatment. This study aims to assess the
functional outcome, quality of life and late sequelae in a representative sample of
long-term survivors of Ewing sarcoma. The data recorded combined with standardized treatment
data covering a 30-year period will produce a data pool that is unique for its magnitude and
will be used for the development of guidelines for further improvements of future bone
sarcoma treatment.
Working plan: The working plan provides for the assessment of functional outcome and quality
of life by means of validated tools (TESS, SF36, PEDQOL) and objectively measuring daily
activity patterns by using the Step Activity Monitor (SAM) in 600 long-term Ewing sarcoma
survivors and a control group of 300 matched healthy subjects. Information on sarcoma
treatment and follow-up is obtained by re-structuring and complementing the database of the
relevant patient cohort (n=3000) from four consecutive nationwide and international clinical
trials between 1980 and 2008. Procedures of local treatment will be evaluated regarding
functional outcome, quality of life, and survival probability and prognostic factors
predicting long-term outcome will be identified.
Exploitation of results: The results will be presented at scientific meetings and will be
published in international journals. Guidelines will be developed regarding improvements in
the treatment, rehabilitation, and social integration of bone sarcoma patients to be
utilized in guiding patients and in the decision process of medical professionals regarding
their treatment. In the long run, the evidence based guidelines on treatment and follow-up
are to be transferred into the health system.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00520936 -
A Study of Pemetrexed in Children With Recurrent Cancer
|
Phase 2 | |
Completed |
NCT00001209 -
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
|
Phase 1 | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT00186992 -
Radiation Therapy to Treat Musculoskeletal Tumors
|
Phase 2 | |
Terminated |
NCT00617890 -
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
|
Phase 2 | |
Completed |
NCT01962103 -
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00474760 -
Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
|
Phase 1 |